Depofemme Special Precautions

Before considering the use of Depofemme, the recipient should undergo an appropriate medical examination of breast and pelvic organs as well as a Papanicolaou test. It should be administered with caution to women with a history of mental depression. Discontinue therapy if necessary. Diabetic patients should be carefully monitored. Masking effects against climacteric signs should be born in mind. It might affect certain endocrine or liver function test.
In case of abnormal result, the test should be repeated 4-6 months after the drug has been withdrawn. It is not recommended to treat secondary amenorrhea or functional uterine bleeding, due to the prolonged action and the resulting difficulty in predicting the time of withdrawal bleeding following injection. In this case, oral therapy should be the choice of treatment. Pathologists should be informed of the recipient's use of Depofemme if relevant specimen is submitted. The following laboratory test may be affected: Gonadotropin level, plasma progesterone level, urinary pregnanediol level, plasma testosterone level (in male), plasma estrogen level (in female), plasma cortisol level, glucose tolerance test, metyrapone test.